---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-014246"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2023-04-25T23:59:59+00:00"
generated_at: "2026-06-16T16:23:12.303370+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma appoints Pamela Garzone to board of directors

## Summary
- Pamela Garzone appointed to board effective April 19, 2023, following recommendation of committee.
- Received option to purchase 40,000 shares vesting over three years.
- Compensation per Director Compensation Policy; standard indemnification agreement.
- No reportable transactions or arrangements with other persons.

## SEC filing metadata
- accession: 0000950170-23-014246
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2023-04-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095017023014246/0000950170-23-014246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095017023014246/cue-20230419.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-014246
- JSON: https://secwatch.observer/filing/0000950170-23-014246.json
- Plain text: https://secwatch.observer/filing/0000950170-23-014246.txt

## Key facts
- Executive change
  Pamela Garzone was appointed as Director at Cue Biopharma, Inc..
  - Action: appointed
  - Role: Director
  source text: On April 19, 2023, Pamela Garzone was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000095017023014246/0000950170-23-014246-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.